Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 12/20 | 0.60 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.60 |
| ▸ | DPP9 | Q86TI2 | 10/20 | 0.60 |
| ▸ | DPP4 | P27487 | 7/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29476460 | 0.87 | DPP8 (0.60) | DPP7DPP8DPP9DPP4NOD1 | |
| SCHEMBL31177108 | 0.85 | DPP8 (0.44) | DPP7DPP8DPP9DPP4NOD1 | |
| SCHEMBL20795868 | 0.83 | DPP4 (0.42) | DPP7DPP8DPP9DPP4NOD1 | |
| SCHEMBL28234596 | 0.83 | DPP4 (0.42) | DPP7DPP8DPP9DPP4NOD1 | |
| SCHEMBL22797764 | 0.83 | DPP4 (0.42) | DPP7DPP8DPP9DPP4NOD1 | |
| SCHEMBL22848364 | 0.83 | DPP4 (0.42) | DPP7DPP8DPP9DPP4NOD1 | |
| SCHEMBL8616850 | 0.81 | DPP8 (0.55) | DPP7DPP8DPP9DPP4NOD1 | |
| SCHEMBL6678282 | 0.81 | DPP8 (0.55) | DPP7DPP8DPP9DPP4NOD1 | |
| SCHEMBL30644787 | 0.80 | NPY4R (0.47) | DPP7DPP8DPP9DPP4NOD1 | |
| SCHEMBL10379813 | 0.80 | NOD1 (0.47) | DPP7DPP8DPP9DPP4NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | DPP7 3248/4885DPP8 2749/4885DPP9 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.